Saturday 17 October 2026
Export PTGX’s income statement to Excel — free account
Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.
128.75
7.80
−5.71%
Follow PTGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 2 | — | — |
+8 more TTM periods Free account |
| 10.98% | (17.06%) | (20.18%) | 7.80% | ||
| 10.34% | (15.94%) | (18.42%) | 7.03% | ||
ROIC |
61.84% | (82.68%) | (208.75%) | 17.14% | |
Return on Tangible Assets |
10.72% | (19.69%) | (24.28%) | 8.41% | |
Average Days of Receivables |
17.37 | 264.46 | 0.96 | 1.02 | |
Free Cash Flow per Share |
1.98 | (1.81) | 0.88 | 1.00 | |
Free Cash Flow |
130.58 | (117.89) | 56.08 | 63.71 | |
Capital Expenditures |
(0.61) | (1.26) | (1.59) | (1.76) | |
| Other line items | |||||
Cash ROIC |
8.04% | (9.80%) | 4.74% | 5.22% | |
Accounts Receivable Turnover |
3.16 | 2.76 | 0.31 | 39.54 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.02) | 0.01 | 0.02 | 0.00 | |
Research and Development Expense of Revenue |
62.12% | 229.72% | 346.16% | 70.66% | |
Selling, General and Administrative Expense of Revenue |
17.20% | 62.64% | 97.47% | 20.25% | |
Share Based Compensation of Revenue |
17.67% | 63.04% | 99.91% | 21.21% | |
Operating CF/Net income |
1.58 | 1.02 | (0.44) | 1.43 | |
Depreciation/Fixed assets |
(0.57) | (0.81) | (1.13) | (1.45) | |
Capex/Depreciation |
0.31 | 0.41 | 0.37 | 0.29 | |
Revenue per Share |
4.28 | 1.14 | 0.72 | 3.28 | |
Operating CF per Share |
1.99 | (1.79) | 0.91 | 1.03 | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.03) | |
Capex to Sales |
0.00 | 0.02 | 0.03 | 0.01 |
Columns are period end dates